Macada Holding, Inc. (PINKSHEETS: MCDA) has decided to award D'Arcy Laboratories a contract to manufacture treatment lotions, soap and shampoo skin products for the Bio-Skin line.

The first three treatment products, the shampoo, soap, and crème, build up and improve the resistance of the skin. These compounds are suitable in particular for preventive treatment in cases of predisposition to chronic skin diseases, for the prevention and treatment of allergic skin reactions, for the treatment of acute skin injuries, for example burns and wounds, as well as in anti-aging of the skin, skin cell rejuvenation and in the treatment of degenerate cells, such as in skin cancers, benign and/or malignant tumors.

"These products address very large markets," said Ron Ritter, President of Macada. "With their superior performance, we look forward to excellent demand."

Inventor Karsten Klingelhöller started his original Regividerm products in 1984 and tried to license Regividerm to leading companies without success and finally lost everything. In 2008, he developed a new and improved product for Lyfetec's Bio-skin line, adding four new ingredients to rejuvenate infected and damaged cells with a cell rejuvenator, silver additive and other FDA-approved ingredients.

Visit our websites at www.lyfetec.com, www.bio-skin.us or www.thenhscenter.com or www.lyfepet.com and www.pembrokegunrange.com to find information about ways you can confirm the benefits of each of the products lines that Lyfetec offers. Consumers will also find supporting research and documents that will help them understand how Lyfetec's supplements work to improve their health, immune system, and overall energy level.

This news release includes forward-looking statements, including with respect to the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements as a result of certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties and events that may be beyond the control of Macada Holding, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, properly price, retain and successfully complete projects, the availability of technical personnel, changes in technology and competition.

Contact: Ron Ritter 954-960-5079

KMA (CE) (USOTC:MCDA)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more KMA (CE) Charts.
KMA (CE) (USOTC:MCDA)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more KMA (CE) Charts.